icn pharmaceuticals inc has about 500 mln dlrs cash and another billion dlrs available credit which intends buy pharmaceutical company chairman milan panic said company annual meeting said acquisition could next months company has nearly two billion dlrs available for acquisition today panic said adding investigating number companies company being studied could possibly acquired friendly basis said panic also said intends seek board approval today repurchase three mln icn common shares discussing possibility acquisition panic said such purchase necessary because icn current marketing capability would not sufficient support distribution company products given icn expectations for market growth worldwide icn principal product ribavirin also known virazole drug marketed number countries and described broad based anti viral company has said its possible applications include treatment some types hepatitis herpes influenza childhood diseases and hemorrhagic fevers icn has been focus consirable investor attention recent months because virazole which has undergone clinical trials possible treatment some aids related diseases panic said today would not discuss drug with aids until food and drug administration completes its review data submitted company said investigation drug being conducted house subcommittee continuing subcommittee and fda have acknowledged conducting separate investigations determine whether not icn witheld data from fda adverse reactions drug virazole approved for marketing aerosol form treatment for infection strikes infants called respiratory syncytial virus reuter 